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One of the hallmarks of cardiac failure is that despite
persistent and often elevated sympathetic stimulation
reﬂecting the body’s effort to compensate for depressed
systemic hemodynamics, the response by the heart is muted.
This can be viewed as a protective mechanism, because
unbridled sympathetic stimulation leads to myocardial
damage, ﬁbrosis, and arrhythmia. Alternatively, it can be
thought of as a direct contributor to depressed function and
reserve capacity worthy of therapeutic targeting. This paradox
has at its core the complexities of beta-adrenergic signaling
and the manner by which it is altered in the failing heart.
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Expression and membrane localization of the beta-
adrenergic receptor (b-AR) is diminished, the balance of
receptor coupling to inhibitory versus stimulatory G-proteins
shifts, and activation of adenylate cyclase required to trans-
duce receptor agonism to cyclic adenosine monophosphate
(cAMP) generation is blunted (1). Combined, these changes
result in net depression of distal signaling mediated princi-
pally by protein kinase A (PKA). Enhancing b-AR signaling
by stimulation with receptor ligands transiently offsets this
down-regulation, but it has chronically proven to be coun-
terproductive, worsening cardiac disease and clinical outcome
(2). However, manipulation of desensitization of the receptor
by preventing its phosphorylation by G-protein–related
kinase 2 (also known as beta-adrenergic receptor kinase 2
[Bark2]), for example, appears to stimulate contraction
without maladaptive consequences (3,4). Thus, useful ther-
apeutic targeting of the myocyte beta-adrenergic pathway
requires an intimate knowledge of the proteins that regulate
it. With the work of Mehel et al. (5) in this issue of the
Journal, we can now add phosphodiesterase type 2 (PDE2) to
the list as a contributor and potential therapy target.
There are a total of 21 different phosphodiesterases, the
enzymes that hydrolyze the cyclic nucleotides cAMP or cyclic
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The PDEs are grouped by their substrate selectivity, with
PDEs that hydrolyze cAMP (PDE4, PDE7, and PDE8),
cGMP (PDE5, PDE6, and PDE9), or both (PDE1, PDE2,
PDE3, PDE10, and PDE11). The cardiac myocyte
expresses PDE1–5, PDE8, and PDE9. These enzymes
regulate localized pools of cyclic nucleotides typically
provided by compartmentalized cyclases that in turn locally
target the cognate protein kinase: PKA for cAMP, and
protein kinase G for cGMP. PDE1 is proposed to play a role
in cardiac hypertrophy and ﬁbrosis primarily via its regulation
of cGMP (7,8), though it is also involved with cAMP
hydrolysis (9). PDE3 is the target of inodilator drugs such as
milrinone and enoximone, because its inhibition enhances
cAMP levels. However, their efﬁcacy is blunted in failing
hearts, in part due to down-regulation of PDE3 expression
(9,10), and long-term inhibition has clinically been associated
with adverse outcomes (11). PDE4 has numerous isoforms
with a variable N-terminus region that encodes a zipcode-like
localizer, parking a given isoform within a speciﬁc intracel-
lular microdomain to target its regulation of PKA signaling
(12). The extent to which PDE4 signaling is inﬂuenced by
heart failure remains unclear. PDE5 was the ﬁrst cGMP-
PDE discovered and received major attention when its role
in erections and pulmonary resistance was ﬁrst established.
More recent work has extended the inﬂuence of PDE5 to the
myocardium and the potential for selective inhibitors to treat
heart disease (13).
PDE2 is a dual-substrate esterase, but its selectivity
depends upon the extent of cAMP and cGMP coactivation,
because cGMP binds to a regulatory GAF-B domain in the
N-terminus to enhance PDE2 cAMP hydrolysis (14). In
this sense, the enzyme is a regulator of cyclic nucleotide cross
talk (15). Prior work, much from the Fischmeister laboratory
that also directed the current study, showed that in adult
myocytes without any co-cAMP stimulation, inhibiting
PDE2 raises cGMP generated by natriuretic peptide stim-
ulation at the plasma membrane (16). However, in the
presence of b-AR agonist, PDE2 targeted cAMP, and its
inhibition augmented adrenergic signaling (17–20). Prior
studies have also shown coactivation of nitric oxide (NO)
synthase coupled to b3-AR plays an important role in the
cGMP-enhanced targeting of PDE2 to cAMP hydrolysis
(18,20,21). What has previously not been examined is the
role, if any, PDE2 regulation may play in diseased condi-
tions where alterations of cGMP and cAMP are prominent.
The new study (5) starts to ﬁll in this knowledge vacuum.
First, the investigators show that PDE2 expression is up-
regulated about 2-fold in human as well as a canine model
of dilated cardiomyopathy. In a rat model of chronic
isoproterenol (ISO)-induced hypertrophy, they found
similar up-regulated PDE2 expression and activity that was
greater against cAMP than cGMP. Selective inhibition of
PDE2 had little impact on elevating cAMP levels in control
hearts, but those subjected to sustained ISO stimulation
showed a modest rise. The rise in cAMP from ISO was
Figure 1
Schematic of b-AR–Coupled Signaling and the
Role Played by PDEs That Hydrolyze cAMP
The beta 1 or 2 adrenergic receptor (b 1/2-AR) couples to G-proteins to activate
adenylate cyclase (AC), that converts 50 -adenosine triphosphate (50 -ATP) into cyclic
adenosine monophosphate (cAMP). The reverse process whereby cAMP is hydro-
lyzed to 50 -AMP is regulated by members of the phosphodiesterases (PDEs). PDE3
and PDE4 have been known to play a role in the normal heartdnegatively
modulating cAMP and, consequently, protein kinase A (PKA)-dependent signaling
that would otherwise enhance calcium cycling, myoﬁlament contraction, L-type
calcium current (LTCC), and other downstream responses to b-AR stimulation. The
new work highlights the role of PDE2dprincipally in the chronically stressed and/
or failing heart. PDE2 is up-regulated in this setting, and primarily hydrolyzes cAMP,
depressing b3-AR stimulation responses. PDE2 is activated by cyclic guanosine
monophosphate (cGMP) binding to a regulatory domain, further stimulating PDE2
hydrolysis of cAMP. This cGMP has been linked to a b3-AR receptor coupled
activation of nitric oxide synthase (NOS) that generates NO-dependent activation
of soluble guanylate cyclase (sGC). This signaling is also enhanced in the failing
heart, further stimulating PDE2 hydrolysis of cAMP to act as an antiadrenergic
brake. Two other PDEs are shown as well. PDE4 targets cAMP only, and plays
a role in the ryanodine receptor and LTCC modulation by PKA, whereas PDE3A
regulates PKA activation at the sarcoplasmic reticulum. PDE3 is also modulated by
cGMPdin this instance, increasing cGMP reduces PDE3 hydrolysis of cAMP due to
competitive inhibition for the latter substrate at the catalytic site. Not shown in this
ﬁgure are PDE1 and PDE8, which may also regulate cAMP pools, though their role
in this regard remains little understood.
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1608much lower in the latter model, and declined more when
costimulated by the NO donor, sodium nitroprusside.
This identiﬁed greater cGMP-activated cAMP hydrolysis
accompanying up-regulated PDE2. Myocyte function
measured as shortening and whole-cell calcium transients
also had a depressed response to short-term ISO when cells
were obtained from the long-term ISO rats, and these were
restored to control levels by coinhibiting PDE2. To further
explore the relevance of up-regulated PDE2, the authors
infected adult myocytes with a control adenovirus or one
expressing PDE2. The latter depressed L-type calcium
current, sarcomere shortening, and whole-cell calcium
transients in response to ISO, analogous to these observed in
the chronic disease model. Up-regulation of PDE2 via gene
transfer was also shown to suppress cellular hypertrophy
induced in response to alpha-receptor agonists.These data support PDE2 as a new player to altered
adrenergic signaling in the diseased heart (Fig. 1). Although
protein expression changes were identiﬁed in human disease,
the current study did not clarify their functionality. They also
showed a lack of similar up-regulation in human hypertrophy
due to aortic stenosis. This is interesting because many
hypertrophic diseases also are characterized by b-AR down-
regulation, and involvement of PDE2 may be different than
that revealed here for dilated heart failure, and worth inves-
tigating further. The use of an experimental chronic ISO
infusion model to study the cellular impact of PDE2 up-
regulation may have favored the results observed, in that
sustained stimulation of a b-AR is itself a major part of the
pathophysiology. Also, several investigators have noted
differences between human and rodent (rat or mouse) PDE
regulation (9), and this may need to be considered. Addi-
tional studies, perhaps in the canine dilated cardiomyopathy
model where PDE2 was also found to be up-regulated, would
be useful. Although the authors demonstrated the potential
to further enhance PDE2 activity using a NO-derived
cGMP stimulus, prior work suggests natriuretic peptide–
linked cGMP synthesis may be a more potent regulator (16).
This remains to be tested, but could have clinical ramiﬁca-
tions, because heart disease is often associated with a reduc-
tion of NO-generated cGMP, due in part to oxidative stress
(22), but a marked rise in NP-derived cGMP.
Last, the key question of whether enhanced PDE2 is
a protective mechanism or one that might be therapeutically
and safely targeted to augment cAMP signaling in failing
hearts remains to be determined. As mentioned earlier, the
monolithic perspective that all forms of cAMP augmenta-
tion are bad has proven incorrect. The exact compartments
in which the cyclic nucleotide is enhanced and its conse-
quent distal signaling are key factors that determine whether
the outcome will improve disease pathophysiology or exac-
erbate it. Although small molecule PDE2 inhibitors are now
available, chronic dosing has not yet been possible and
awaits further drug development. Genetic knockout models
have also not been successfully generated. Thus, the real
impact of modulating PDE2 in vivo remains to be tested.
The work by Mehel et al. (5) identifying PDE2 as a likely
relevant actor in the b-AR-heart disease drama will hope-
fully incentivize further developments in the ﬁeld so this
role and the potential value of targeting PDE2 as therapy
can be tested.
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